JAGX · Jaguar Health, Inc.
AI read · Neutral
The AI's read
Jaguar shifted toward rare GI indications, reported promising crofelemer trial data, and secured an $18M upfront licensing payment with $17M in potential milestones. That provides near-term cash and a non-dilutive path if clinical programs confirm benefit. Market action was negative. JAGX is down 5.8% after revenue for prescription products plunged 60% and net loss widened, so the market is skeptical about execution and timing. We lean neutral. The upside is real but binary and long-dated, while tiny market cap, low liquidity, and dependence on future readouts make this high risk.